Abstrait

Efficacy and safety of mometasone furoate nasal spray in allergic rhinitis, acute rhinosinusitis and nasal polyposis

Catherine B Small and Ariel Teper

Seasonal and perennial allergic rhinitis, acute rhinosinusitis and nasal polyposis are common inflammatory conditions of the airway that markedly impair patient health and quality of life. Treatment guidelines for each of these conditions recommend intranasal corticosteroids, which help to alleviate symptoms by reducing inflammation. One of the most extensively studied intranasal corticosteroids for these conditions is mometasone furoate nasal spray (MFNS). In more than 20 clinical trials, MFNS has been shown to reduce both objective and subjective signs of inflammation and promotes rapid resolution of nasal, sinus and ocular symptoms in adults, adolescents and children. MFNS is well-tolerated and local adverse events are generally mild and self-limiting, usually resolving without discontinuation of therapy. The low systemic bioavailability (<0.1%) and high first-pass metabolism of MFNS also reduce its risk for systemic adverse events.